

Supplementary Table 4. Safety event after medication between experimental drug (DW1601) and control (DW16011 or *Pe/argonium sidoides*)

Variable	DW1601 (n = 68)	DW16011 (n = 70)	<i>P. sidoides</i> (n = 64)	<i>p</i> value ^a	<i>p</i> value ^b
TEAE	5 (7.5)	6 (8.6)	6 (9.2)	0.811	0.713
Dry mouth	2 (3.0)	1 (1.4)	0		
Nausea	1 (1.5)	0	1 (1.5)		
Dyspepsia	0	0	1 (1.5)		
Gastritis	0	0	1 (1.5)		
Somnolence	1 (1.5)	3 (4.3)	2 (3.1)		
Dizziness	0	1 (1.4)	0		
Face edema	1 (1.5)	1 (1.4)	0		
Pyrexia	0	0	1 (1.5)		
Upper respiratory infection	0	0	1 (1.5)		
Nasal dryness	0	1 (1.4)	0		
ADR	4 (6.0)	6 (8.6)	4 (6.2)	0.559	0.965
Dry mouth	2 (3.0)	1 (1.4)	0		
Nausea	1 (1.5)	0	1 (1.5)		
Dyspepsia	0	0	1 (1.5)		
Somnolence	1 (1.5)	3 (4.3)	2 (3.1)		
Dizziness	0	1 (1.4)	0		
Nasal dryness	0	1 (1.4)	0		
SAE	0	0	0	NA	NA
SADR	0	0	0	NA	NA

Values are presented as number (%).

TEAE, treatment-emergent adverse event; ADR, adverse drug reaction; SAE, serious adverse event; SADR, serious adverse drug reaction; NA, not applicable.

^a*p* value was calculated using Pearson's chi-square test for the difference of score between DW1601 and DW16011 groups.

^b*p* value was calculated using Pearson's chi-square test for the difference of score between DW1601 and *P. sidoides* groups.